Drug Profile
CGS 306
Alternative Names: CGS-306Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator CapGenesis Therapeutics
- Class Antineoplastics; Flavonoids; Small molecules
- Mechanism of Action Autophagy stimulants; Cytochrome P 450 enzyme system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Xeroderma pigmentosum
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Xeroderma pigmentosum in USA (Topical)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Xeroderma-pigmentosum in USA (Topical)
- 30 Nov 2015 Preclinical trials in Xeroderma pigmentosum in USA (Topical) before November 2015